- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05708716
Diet and Cognitive Training in Hematologic Cancer Survivors
A Multi-component Non-pharmacological Intervention to Improve Cognitive Outcomes in Hematologic Cancer Survivors
The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are:
- is it feasible to combine a ketogenic diet supplementation and online cognitive training in an intervention program
- will patients using the combined intervention program have improved cognitive functioning compared to those who don't use it
- how long will the intervention programs effects last
Participants randomized to the intervention arm will consume an exogenous ketogenic supplementation and use an online cognitive training program for 12 weeks, while waitlist arm functions as a control group and will receive the online cognitive training only after a wait period of 12 weeks. Researchers will compare the intervention and waitlist control groups to see if the intervention improves cognitive functioning.
Study Overview
Status
Conditions
Detailed Description
The investigators propose using "off-the-shelf" products in a 12-week multicomponent cognitive intervention program to address the cognitive impairment in outpatient hematologic malignancy survivors. The program includes two components: i) A modified ketogenic diet using an exogenous ketogenic supplementation using the KetoCal product ([https://shop.myketocal.com/product/ketocal-41-lq]) and ii) online cognitive training using Lumosity program (http://www.lumosity.com/).
A ketogenic diet is characterized by high fat, moderate protein and very low carbohydrate intake. Participants will follow a modified ketogenic diet consuming exogenous Ketocal tetrapaks daily to substitute ~700 calories of their daily calorie needs and limit their carbohydrate intake while maintaining an eucaloric diet. The KetoCal is a nutritionally complete, ready-to-feed ketogenic meal replacement product. The study goal is to achieve safe and tolerable levels of mild nutritional ketosis (0.5-2mmol/L betahydroxybutyrate (BHB) blood concentration). Diet education will be provided to participants on how and when to consume the KetoCal formula, foods and beverages consistent with a ketogenic diet and foods and beverages to avoid, and how to measure the ketosis using a breathalyzer daily. Safety and Tolerability monitoring will occur by recording treatment-emergent and/or treatment-related adverse events, regular monitoring of weight and satiety levels, and routine laboratory testing using fasting blood samples at baseline and 12 weeks.
The Lumosity program offers over 60 tasks in game-like format that cover the main cognitive domains: processing speed, working memory, attention and executive function. Training will involve a daily session of 5 training tasks for 12 weeks. Each time the patient is logged in for a session, a customized report will be generated by the Lumosity program to capture performance information.
Participants' cognitive functioning will be assessed at baseline and 12 weeks using objectively measured cognitive function to estimate the preliminary efficacy of intervention program; and at 24 weeks to examine the sustained effects of the multi-component intervention program.
The findings from this project will inform a definitive phase III trial of a multi-component intervention to improve cognitive outcomes in patients with hematologic malignancy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Noha M Sharafeldin, MD, MSc, PhD
- Phone Number: 2056382144
- Email: nsharafeldin@uabmc.edu
Study Contact Backup
- Name: Lindsey Hageman, MPH
- Phone Number: 2056382139
- Email: lihageman@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Noha Sharafeldin, MD, MSc, PhD
- Phone Number: 205-638-2144
- Email: nsharafeldin@uabmc.edu
-
Contact:
- Lindsey Hageman, MPH, CCRP
- Phone Number: 2056382139
- Email: lihageman@uabmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult with hematologic malignancy diagnosed at age ≥21 years
- Outpatient at least 3 months from completion of blood or marrow transplant (BMT) or at least 6 months from diagnosis for patients not treated with BMT
- Evidence of mild-to-moderate cognitive impairment using either the Modified Telephone Interview for Mild Cognitive Impairment (TICS-M) or PROMIS 8a short form raw score = 19 -37
- Have daily access to an internet-connected home computer
- Can fluently read and write in English
- Can understand and sign the study-specific Informed Consent Form
Exclusion Criteria:
- History of pre-existing neurological disorder or documented major psychiatric disorder
- Significant auditory, visual, or motor impairments
- History of color blindness
- Participated in neuropsychological intervention within the past 6 months
- Evidence of active chronic graft vs. host disease (GvHD) for allogeneic BMT
- History of pre-existing metabolic disease
- Allergies to soy or milk
- Body Mass Index (BMI) ≤20
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diet and Cognitive Training
The arm will follow a modified ketogenic diet using an exogenous ketogenic formula (KetoCal) and use the online cognitive training program Lumosity at time of enrollment on the study.
|
Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
Other Names:
Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
Other Names:
|
Active Comparator: WaitList Control
The arm will only use the online cognitive training program Lumosity 3 months after enrollment in the study.
|
Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hematologic malignancy patients completing the 2-arm 12wk randomized wait-listed trial of the multicomponent intervention of modified ketogenic diet and cognitive training
Time Frame: 12 weeks
|
Number of participants completing the 12 week intervention
|
12 weeks
|
Change in cognitive function global deficit score (GDS) from baseline to 12 wks, comparing patients on the multicomponent active arm to the waitlist arm (prior to receiving cognitive training)
Time Frame: Baseline to 12 weeks
|
Change in cognitive function will be measured using the cognitive function global deficit score (GDS) at baseline and 12 weeks comparing both active and waitlist arms.
The neuropsychological test battery will include the following tests: D-KEFS Verbal Fluency, DKEFS Color-Word Interference, D-KEFS Trail Making, WAIS-IV Digit-Symbol Coding, WAIS-IV Digit Span, WAIS-IV Letter-Number Sequencing, WMS-IV Logical Memory, CVLT-II).
Raw scores from the neuropsychological test battery will be transformed to standardized T-scores (mean=50; SD=10) using published normative data.
T-scores will be converted to a deficit score ranging from 0 (no impairment) to 5 (severe impairment) and averaged across all tests to calculate the GDS.
A lower GDS score means better cognitive function.
|
Baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive function global deficit score (GDS) from baseline to 12 wks in patients on the multicomponent active arm compared to change in cognition from 12 wks to 24 wks in patients on the waitlist arm (following receiving cognitive training)
Time Frame: Baseline to 12 weeks for the multicomponent active arm and from 12 weeks to 24 weeks for the waitlist arm
|
Change in cognitive function will be measured using cognitive function global deficit score (GDS) at baseline and 12 weeks on the multicomponent active arm and 12 weeks to 24 weeks on the waitlist arm following receiving the cognitive training only.
The neuropsychological test battery will include the following tests: D-KEFS Verbal Fluency, DKEFS Color-Word Interference, D-KEFS Trail Making, WAIS-IV Digit-Symbol Coding, WAIS-IV Digit Span, WAIS-IV Letter-Number Sequencing, WMS-IV Logical Memory, CVLT-II).
Raw scores from the neuropsychological test battery will be transformed to standardized T-scores (mean=50; SD=10) using published normative data.
T-scores will be converted to a deficit score ranging from 0 (no impairment) to 5 (severe impairment) and averaged across all tests to calculate the GDS.
A lower GDS score means better cognitive function.
|
Baseline to 12 weeks for the multicomponent active arm and from 12 weeks to 24 weeks for the waitlist arm
|
Change in cognitive function global deficit score (GDS) from 12 wks to 24 wks in patients on the multicomponent active arm
Time Frame: 12 weeks to 24 weeks
|
Change in cognitive function will be measured using cognitive function global deficit score (GDS) at 12 weeks to 24 weeks on the multicomponent active arm.
The neuropsychological test battery will include the following tests: D-KEFS Verbal Fluency, DKEFS Color-Word Interference, D-KEFS Trail Making, WAIS-IV Digit-Symbol Coding, WAIS-IV Digit Span, WAIS-IV Letter-Number Sequencing, WMS-IV Logical Memory, CVLT-II).
Raw scores from the neuropsychological test battery will be transformed to standardized T-scores (mean=50; SD=10) using published normative data.
T-scores will be converted to a deficit score ranging from 0 (no impairment) to 5 (severe impairment) and averaged across all tests to calculate the GDS.
A lower GDS score means better cognitive function.
|
12 weeks to 24 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Noha M Sharafeldin, MD, MSc, PhD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 161221006
- R03CA270671 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
Stanford UniversityRecruitingMild Cognitive Impairment | Subjective Cognitive ImpairmentUnited States
-
Fondazione Don Carlo Gnocchi OnlusUniversity of Florence; Consorzio di Bioingeneria e Informatica Medica; Gutenberg...CompletedCognitive Dysfunction | Mild Cognitive Impairment | Vascular Cognitive ImpairmentItaly
-
University of California, Los AngelesCompletedMild Cognitive Impairment (MCI) | Age-associated Cognitive ImpairmentUnited States
-
Universidad de ZaragozaNot yet recruitingMild Cognitive Impairment | Randomized Controlled Trial | Subjective Cognitive Impairment
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Region SkaneLund University; Berry LabCompletedMemory Impairment | Cognitive Impairment, MildSweden
-
University of GeorgiaApplied Universal Dynamics, Corp.; Van Robotics, Inc.Active, not recruitingRobot-assisted Cognitive Training for Lonely Older Adults With Mild Cognitive Impairment (MCI) (MCI)Cognitive Change | Aging | Cognitive Impairment, MildUnited States
-
University Health Network, TorontoRecruiting
-
Wake Forest University Health SciencesActive, not recruiting
Clinical Trials on Modified ketogenic diet using an exogenous ketogenic formula
-
Instituto Nacional de Ciencias Medicas y Nutricion...University of OxfordRecruitingKetosis | Heart Failure With Reduced Ejection FractionMexico
-
Kuopio University HospitalDeakin UniversityRecruitingPsychotic Disorders | Schizophrenia | Psychosis | Psychosis; AcuteFinland
-
Birmingham and Solihull Mental Health NHS Foundation...UnknownEpilepsyUnited Kingdom
-
Loma Linda UniversityEnrolling by invitationTraumatic Brain InjuryUnited States
-
Oslo University HospitalCompleted
-
Johns Hopkins UniversityEnrolling by invitationEpilepsy | Coronary Disease | Cardiovascular Disease | Hypercholesterolemia | Heart Disease | Cerebrovascular Disease | Seizure | Carotid Intimal Medial Thickness 1United States
-
Yonsei UniversityCompletedKetogen-based Therapeutic Diet | Pancreaticobiliary CancerKorea, Republic of
-
Tehran University of Medical SciencesCompleted
-
Johns Hopkins UniversityCompletedMild Cognitive Impairment | Probable Alzheimer's DiseaseUnited States
-
All India Institute of Medical Sciences, New DelhiCompleted